1. Sweden Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
aXichem AB Class A

aXichem AB Class A

SSTO:AXIC_A
1.93
SEK
0.00
(0.00%)
-0.25EPS
111.41MMarket Cap
Nov 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.05
- -
- -
- -
0.02
0.02
0.07
0.26
0.29
0.09
0.22
0.31
0.26
Basic EPS, GAAP
-0.77
-0.79
-0.89
-0.61
-0.47
-0.64
-0.76
-0.81
-0.88
-1.01
-1.02
-0.46
-0.3
-0.25
Free Cash Flow per Basic Share
-1.29
-1.37
-1.49
-1.07
-0.7
-0.71
-0.96
-1.13
-1.19
-1.26
-1.02
-0.46
-0.27
-0.13
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.25
2.27
2.37
2.65
2.17
1.84
4.03
3.22
3.25
2.31
2.17
1.18
0.89
0.82
Tangible Book Value per Share
1.76
-0.05
0.23
0.8
0.12
-0.33
1.85
0.74
0.74
-0.14
0.2
0.4
0.12
0.15
Basic Weighted Avg Shares
5
7
8
10
16
16
17
17
17
17
20
39
60
63
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
1
4
5
2
9
18
16
Operating Margin (%)
- -
-1,471.01
- -
- -
- -
-2,809.88
-3,623.03
-1,101.3
-345.48
-290.49
-957.32
-184.68
-94.82
-94.23
Depreciation Expense
- -
- -
- -
- -
- -
1
2
2
2
4
4
4
5
5
Net Income, GAAP
-4
-6
-7
-6
-7
-10
-13
-14
-15
-17
-21
-18
-18
-16
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-1,496.81
- -
- -
- -
-2,885.76
-3,657.73
-1,101.39
-346.01
-344.66
-1,150.41
-207.85
-95.59
-95.36
Working Capital
3
4
6
16
6
-5
31
12
13
-2
5
24
7
10
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
25
19
26
41
34
29
67
54
56
40
49
70
53
55
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-22.21
-25.67
-32.84
-17.96
-19.62
-31.53
-26.07
-22.37
-27.45
-35.73
-46.87
-30.03
-28.67
-26.68

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
68
68
Market Capitalization
122
106
111

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
15
18
15
Cash, Cash Equivalents & STI
3
4
3
Accounts Receivable, Net
4
- -
- -
Inventories
8
8
5
Total Current Liabilities
8
4
4
Payables & Accruals
- -
- -
- -
ST Debt
5
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.27%
3.37%
-24.63%
Free Cash Flow
3.81%
-2.92%
-11.12%
Net Income, GAAP
10.31%
6.24%
-1.01%
Sales/Revenue/Turnover
- -
139.08%
115.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
6
1
1
9
2025
3
7
5
4
18
2026
4
4
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.25
-0.03
-0.15
-0.1
-0.46
2025
-0.1
-0.06
-0.05
-0.09
-0.3
2026
-0.05
-0.06
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nils Torsten Helsing
Full Time Employees
7
Sector
Process industries
Industry
Chemicals: specialty
Address
Södergatan 26 Malmö SN Sweden 211 34
IPO Date
Jul 10, 2008
Website
axichem.se
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
Dow Inc. (NYSE:DOW)
Business
aXichem AB (publ) (AXIC-A.ST), a Sweden-based biotechnology company founded in 1999 and headquartered in Malmö, develops and commercializes patented natural analogue ingredients derived from synthetic phenylcapsaicin for animal health, nutraceuticals, life sciences, and industrial applications; core products include aXivite, a stable capsaicin analogue for dietary supplements, weight management, muscle health, and pharmaceutical bio-enhancement; aXiphen-feed (aXiphen®), a feed additive enhancing growth, feed efficiency, and salmonella resistance in poultry, pigs, piglets, and now dairy cattle; and aXiphen-bio, a bio-repellent for marine antifouling on vessels, pest control in agriculture, forestry, and cable protection. The company operates primarily in Europe, Latin America (notably Brazil via distributor Chr. Olesen Group), Scandinavia, the United States, Mexico, Spain, and Asia, targeting feed producers, dietary supplement manufacturers, pharmaceutical firms, and industrial users with eco-friendly, high-purity, nature-identical solutions compliant with EU novel food regulations, US GRAS status, and biocidal directives. Recent developments encompass a November 2025 fast-track application in Brazil with Chr. Olesen for phenylcapsaicin as a dairy cattle feed additive following successful poultry tests and a SEK 7 million order; ongoing expansion of Uriach's Aquilea® melatonin product with aXivite® into Portugal, Germany, Austria, and Romania after its 2024 Spain launch and EUR 400,000 commitment fulfillment; new 2025 aXivite® orders from US distributor SEE Nutrition (SEK 3 million), Spanish Pharmafoods, and Silvaco A/S; commercial aXiphen trials in Brazil; OmneDiem® US launches for exercise and health; an intra-group share transfer among LMK companies maintaining 16.4% ownership; and COO Erik Lager's April 2025 appointment.